Results 101 to 110 of about 754,510 (299)

Comparison of systematic and combined biopsy for the detection of prostate cancer

open access: yesAsian Journal of Andrology
Systematic prostate biopsy has limitations, such as overdiagnosis of clinically insignificant prostate cancer and underdiagnosis of clinically significant prostate cancer.
Jin-Lun Huang   +12 more
doaj   +1 more source

eipm/ai-biopsy: v1.2.4.patched20221111

open access: yes, 2022
Biopsy-free prediction of prostate cancer aggressiveness using deep learning and radiology ...
Alexandros Sigaras   +2 more
core   +1 more source

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan   +9 more
wiley   +1 more source

MRI-targeted or standard biopsy for prostate-cancer diagnosis [PDF]

open access: yes, 2018
Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who ...
Pinto, Peter   +236 more
core   +2 more sources

The VCPIP1‐UBE3A Deubiquitination‐Ubiquitination Cascade Contributes to Castration‐Resistant Prostate Cancer Progression

open access: yesAdvanced Science, EarlyView.
VCIPIP1 emerges as a molecular link between protein stability and prostate cancer progression. By deubiquitinating and stabilizing UBE3A, VCIPIP1 promotes p53 degradation and progression to castration‐resistant prostate cancer. Elevated VCIPIP1 expression is associated with shorter castration‐resistant prostate cancer–free survival, highlighting the ...
Fei Lin   +9 more
wiley   +1 more source

Non‐Invasive Assessment of Perineural Invasion Density: A Novel Marker for Prognosis and Treatment Stratification in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
This study establishes perineural invasion density (PNID) as a superior prognostic marker in prostate cancer, outperforming conventional perineural invasion in predicting biochemical recurrence and radiographic progression. Concurrent β–blocker use is associated with favorable outcomes exclusively in High–PNID patients. An MRI–based deep learning model
Bohao Liu   +20 more
wiley   +1 more source

The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens

open access: yesBMC Cancer, 2018
Background Prostate biopsy is the most common method for the diagnosis of prostate cancer and the basis for further treatment. Confirmation using radical prostatectomy specimens is the most reliable method for verifying the accuracy of template-guided ...
Zhipeng Mai   +7 more
doaj   +1 more source

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study [PDF]

open access: yes, 2011
This article is available through a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. Copyright @ 2011 Cancer Research UK.Background: Contemporary screening for prostate cancer frequently identifies small volume, low-grade ...
Catto, J. W. F.   +63 more
core   +1 more source

DTX3 Suppresses the NPM3–RUVBL1 Axis to Inhibit Homologous Recombination Repair and Abrogate Tumor Radioresistance

open access: yesAdvanced Science, EarlyView.
Deltex 3 (DTX3) catalyzes K27‐linked ubiquitination of nucleophosmin 3 to disrupt homologous recombination repair and reverse tumor radioresistance. Low DTX3 predicts poor survival and radiotherapy recurrence, serving as a radiosensitizing therapeutic target.
Jia‐Hao Xiao   +9 more
wiley   +1 more source

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

open access: yesAdvanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

Home - About - Disclaimer - Privacy